Toxicology and Pharmacokinetics of BOPP in a Canine Model

Abstract

The development of new tumor-selective boron compounds for the treatment of glioblastoma multiforme, melanoma and other malignancies only begins with the synthesis of new compounds. Compounds that show initial promise as a result of cell culture and small animal studies face the further requirement that they exhibit acceptable levels of toxicity in larger animal models. Furthermore the pharmacokinetic behavior of such compounds as determined in small animals must be re-examined at the level of larger mammals in order to more closely approximate their expected behavior in human Phase 1 biodistribution trials.